Lu O. Sun

Jun 26, 2024 | nature.com | Lu O. Sun |Xiang Zhou |Jie Yang

AbstractA long-standing but poorly tested hypothesis in plant ecology and evolution is that biotic interactions play a more important role in producing and maintaining species diversity in the tropics than in the temperate zone. A core prediction of this hypothesis is that tropical plants deploy a higher diversity of phytochemicals within and across communities because they experience more herbivore pressure than temperate plants.

May 8, 2024 | nature.com | Richard Everson |Willy Hugo |Lu O. Sun |Joseph K. Antonios |Melissa Bu |Sara Khattab | +9 more

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and delayed disease progression. These findings suggest that combining ATL-DC with poly-ICLC can induce a polarized interferon response in circulating monocytes and CD8+ T cells, which may represent an important blood biomarker for immunotherapy in this patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01204684. Autologous tumor lysate (ATL) dendritic cell (DC) vaccination can induce local and systemic anti-tumor immune responses in malignant glioma patients. In this randomized phase II clinical trial, the authors evaluate the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to ATL-DC vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas.

Apr 23, 2024 | pubs.rsc.org | Fanqi Meng |Lu O. Sun |Yueying Liu |Xiang Li

Theoretical investigation of the reaction mechanism of THP oxidative rearrangement catalysed by BBOX γ-butyrobetaine hydroxylase (BBOX) is a non-heme FeII/2OG dependent enzyme that is able to perform two different kinds of catalytic reactions on 3-(2,2,2-trimethylhydrazinium) propionate (THP) to produce distinct catalytic products. Although the structure of BBOX complexed with THP has been resolved, the details of its catalytic mechanism are still elusive.